看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。! a; p4 b6 j; ]* N" L* W2 a) O
, N( i" C0 C) \# Z- ? G
. c5 l& H: C2 B# _' o( `) hCurrently available feasibility data for possible combination strategies. 3 Y2 [% Y& h2 ^$ U+ W0 Y
————————————————————————————————
* l6 z' f2 w- B) x" H" G: nCombination Feasibility according to preliminary data $ v/ B7 ~3 _, Y6 G* x R% n
——————————————————————————————————/ n: P! X* r+ c5 H* p- [/ t: u0 U
Bevacizumab + sorafenib Yes, reduced dose " T+ I) T4 P0 T+ Y
Bevacizumab + sunitinib† No
% x1 E2 S1 |8 V5 dBevacizumab + temsirolimus Yes
% J3 W! H3 H9 @# ?) N7 N/ d& o9 QBevacizumab + everolimus Yes - [" m+ D' L- m( l2 i. L3 |# X
Sorafenib + sunitinib ?
0 X# s$ o5 Y5 |( M) WSorafenib + temsirolimus Yes, reduced dose ; z% Z1 }2 j ~
Sorafenib + everolimus Yes, reduced dose
$ b, F$ D9 R& ~' NSunitinib + temsirolimus† No
/ C/ U( ^* }* D0 ?4 w/ z: iSunitinib + everolimus ? 5 q9 [ }$ d8 T
Temsirolimus + everolimus ? 8 u5 `" B* H1 `: h" g
————————————————————
7 \6 U" p- w- [. S9 V8 Z+ k†Led to US FDA warning.
* ]' h* c! k" m- h?: As yet unattempted combination.
! F" J; r/ h5 Z) M1 \( f |